Tags

Type your tag names separated by a space and hit enter

Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.
Clin Neuropharmacol. 2010 Nov-Dec; 33(6):271-5.CN

Abstract

OBJECTIVE

The objective of the study was to demonstrate whether the N-methyl-D-aspartate antagonist, amantadine, can safely ameliorate tardive dyskinesia (TD) without deteriorating the mental state of the patients.

METHODS

Twenty-two TD patients, with a mean age 52 years, participated in the study. A double-blind, placebo-controlled, crossover design was used. Patients were randomly assigned to receive either amantadine or placebo for 2 weeks followed by a washout period of 4 days. Subsequently,the groups were crossed over, and the procedure repeated. Participants received amantadine (100 mg) or placebo. Tardive dyskinesia was assessed by means of the Abnormal Involuntary Movements Scale(AIMS). The primary efficacy end point was changes in AIMS score, at baseline and at the end of the 2-week treatment period.

RESULTS

After amantadine treatment, patients exhibited a reduced average score of total AIMS (from 13.5 before treatment to 10.5 after treatment,P = 0.000), of facial and oral AIMS (from 5.5 before treatment to 4.2 after treatment, P = 0.002), of extremity AIMS (from 4.18 before treatment to 2.8 after treatment, P = 0.000), and of severity AIMS (from 2.04 before treatment to 1.54 after treatment, P = 0.002). With amantadine,the average total AIMS reduction was 21.81%. On the contrary with placebo treatment, no reduction was noted.In addition, amantadine administration exhibited a positive effect,which was statistically significant for incapacitation and Clinical Global Impression score. Amantadine did not alter any of the cognitive measures used in this study, as Mini-Mental State Examination, distress, and Brief Psychiatric Rating Scale.

CONCLUSIONS

Amantadine may be an effective and safe treatment for TD. The severity of TD movements in patients receiving amantadine improved significantly more than in those receiving placebo, as measured by the AIMS score.

Authors+Show Affiliations

Department of Psychiatry, University Hospital of Ioannina, Ioannina, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

21121175

Citation

Pappa, Sofia, et al. "Effects of Amantadine On Tardive Dyskinesia: a Randomized, Double-blind, Placebo-controlled Study." Clinical Neuropharmacology, vol. 33, no. 6, 2010, pp. 271-5.
Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33(6):271-5.
Pappa, S., Tsouli, S., Apostolou, G., Mavreas, V., & Konitsiotis, S. (2010). Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clinical Neuropharmacology, 33(6), 271-5.
Pappa S, et al. Effects of Amantadine On Tardive Dyskinesia: a Randomized, Double-blind, Placebo-controlled Study. Clin Neuropharmacol. 2010 Nov-Dec;33(6):271-5. PubMed PMID: 21121175.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. AU - Pappa,Sofia, AU - Tsouli,Sofia, AU - Apostolou,George, AU - Mavreas,Venetsanos, AU - Konitsiotis,Spiridon, PY - 2010/12/3/entrez PY - 2010/12/3/pubmed PY - 2011/3/30/medline SP - 271 EP - 5 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 33 IS - 6 N2 - OBJECTIVE: The objective of the study was to demonstrate whether the N-methyl-D-aspartate antagonist, amantadine, can safely ameliorate tardive dyskinesia (TD) without deteriorating the mental state of the patients. METHODS: Twenty-two TD patients, with a mean age 52 years, participated in the study. A double-blind, placebo-controlled, crossover design was used. Patients were randomly assigned to receive either amantadine or placebo for 2 weeks followed by a washout period of 4 days. Subsequently,the groups were crossed over, and the procedure repeated. Participants received amantadine (100 mg) or placebo. Tardive dyskinesia was assessed by means of the Abnormal Involuntary Movements Scale(AIMS). The primary efficacy end point was changes in AIMS score, at baseline and at the end of the 2-week treatment period. RESULTS: After amantadine treatment, patients exhibited a reduced average score of total AIMS (from 13.5 before treatment to 10.5 after treatment,P = 0.000), of facial and oral AIMS (from 5.5 before treatment to 4.2 after treatment, P = 0.002), of extremity AIMS (from 4.18 before treatment to 2.8 after treatment, P = 0.000), and of severity AIMS (from 2.04 before treatment to 1.54 after treatment, P = 0.002). With amantadine,the average total AIMS reduction was 21.81%. On the contrary with placebo treatment, no reduction was noted.In addition, amantadine administration exhibited a positive effect,which was statistically significant for incapacitation and Clinical Global Impression score. Amantadine did not alter any of the cognitive measures used in this study, as Mini-Mental State Examination, distress, and Brief Psychiatric Rating Scale. CONCLUSIONS: Amantadine may be an effective and safe treatment for TD. The severity of TD movements in patients receiving amantadine improved significantly more than in those receiving placebo, as measured by the AIMS score. SN - 1537-162X UR - https://www.unboundmedicine.com/medline/citation/21121175/Effects_of_amantadine_on_tardive_dyskinesia:_a_randomized_double_blind_placebo_controlled_study_ L2 - https://doi.org/10.1097/wnf.0b013e3181ffde32 DB - PRIME DP - Unbound Medicine ER -